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Background
Nowadays, prostate cancer is one of the main lethal cause from cancer patients world-
wide, and more than one-third of newly diagnosed male cancer in Europe and USA was 
prostate cancer (Crawford 2003; Parkin et al. 2001). Despite the hormone therapy was 
effective in early stage, many patients with metastatic potential eventually progress to 
an androgen-resistant state (Sandblom and Varenhorst 2001; Zitzmann et  al. 2005). 
Although there were several treatment methods applied in the clinic, but none showed a 
survival benefit in hormone independent prostate cancer patients (Sternberg 2003).
Prostate-specific membrane antigen (PSMA) as a member of trans-membrane folate 
hydrolase family, which could enhanced the expression level in prostate cancer tis-
sue other than benign or neoplastic epithelial prostate cells (Bostwick et al. 1998; Ross 
et  al. 2003). A weak extra prostatic expression of PSMA has been reported in some 
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other tissues (Renneberg et al. 1999; Silver et al. 1997) Therefore, the Hu591 monoclo-
nal antibody(mAb) targeting the PSMA extracellular domain, has been applied to the 
prostate cancer therapy (Liu et al. 1997; Nanus et al. 2003). An 111In-labeled monoclo-
nal antibody (Capromab pendetide, ProstaScint) could targeted to PSMA and used for 
imaging lymph node metastases. Recently, Zitzmann et al., have reported a novel pep-
tide DUP1 with specificity for PSMA-negative prostate tumor cell lines, such as DU-145 
and PC-3, which was identified by phage display techniques.
Peptide modified polymeric micelles have been investigated extensively, and these 
works are quite extraordinary, impressive, and laid a solid foundation for our study. In 
recent years, Torchilin et al., have reported that the monoclonal antibody (mAb)-modi-
fied PEG-PE micelles could recognize and bind to numerous tumor cells but not normal 
cells in vitro (Torchilin et al. 2003). Several researchers have reported that the synergeti-
cally therapeutic efficacy of chemotherapy by polymer–peptide or drug–peptide conju-
gates, which leads to amplifying apoptosis induction activity in the tumor or enhancing 
tumor targeting (Liu et al. 2008; Dharap et al. 2005). In our previously studies, we have 
reported the fibroblast growth factor (FGF) fragment peptide modified micelles could 
significantly enhanced the cytotoxicity of paclitaxel for murine lewis lung cancer (LLC) 
cells, which were further confirmed by some subsequent experiments in vitro (Cai et al. 
2011). These antibodies or peptides conjugated micelles could enhanced the specific 
uptake of drugs and/or genes by targeted cells actively. To our knowledge, nanotech-
nology is widely applied to prepare a novel nano-formulation of hydrophobic drugs for 
enhancing cancer therapy efficiency (Gong et al. 2013). By encapsulating into nanoscale 
vectors, hydrophobic drugs could form stably disperse morphology in water (Wagner 
et  al. 2006; Jain and Stylianopoulos 2010; Li et  al. 2012). Moreover, amphiphilic poly-
meric micelles have widely applied in drug delivery system (DDS) for anti-tumor agents, 
in which the hydrophilic shell helps the escape from the clearance by RES (reticuloen-
dothelial system) and the hydrophobic core wraps drug via hydrophobic interactions or 
hydrogen bonds (Gong et al. 2010, 2011; He et al. 2012; Li et al. 2012, 2013; Wu et al. 
2012; Ma et al. 2013; Zhang et al. 2014; Zeng et al. 2014). Furthermore, their nano-size 
will improve the anti-tumor effects through the enhanced permeability and retention 
(EPR) effect (Iyer et al. 2006; Muggia 1999; He et al. 2013).
In this work, DUP1 peptide was obtained by solid phase peptide synthesis, and DUP1 
modified polymeric micelles were prepared using a solid dispersion method (Fig.  1). 
Cytotoxicity, apoptosis, cellular uptake, and drug release behavior of paclitaxel (PTX) 
loaded Chol–PEG–DUP1 micelles (Chol–PEG–DUP1–M-PTX) were studied in detail. 
Hence, this novel tumor targeting DDS may have several functions for prostate tumor 
therapy: first of all, the Chol–PEG–DUP1 micelles could provide prolonged drug effects 
because of their sustained release characteristic, and protect the encapsulated agent 
from enzymatic degradation; secondly, the nanoscale size of the micelles would improve 
the targeting efficiency and therapeutic activity of small molecular antitumor drug via 
EPR effect; finally, the DUP1 fragment could specifically target to the PSMA-negative 
tumor cells, resulting in special uptake of antitumor drugs.
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Methods
Materials and cell lines
Cholesterol (Chol) monomethoxy poly(ethylene glycol) (MW 2000, mPEG2000) and 
poly(ethylene glycol) (MW 2000, PEG2000), was obtained from BoAo Biological Tech-
nology (Shanghai, China). The 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenltetrazolium 
bromide (MTT), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDCI), and 4-dimethylaminopyridine (DMAP) 1, 8-Diazabicyclo(5.4.0)undec-7-ene 
(DBU), Coumarin-6, fmoc–l-phenylalanine (fmoc–phe), and succinic anhydride (suc) 
were Obtained from Sigma-Aldrich (St. Louis, MO, USA). 3-Maleimidopropionic acid 
N-succinimidyl ester (BMPS) was purchased from Jiaxing Biomatix Co. Ltd. (Jiaxing, 
China). Soya phosphatidylcholine (SPC) was from Lucas Meyer (Hamburg, Germany). 
Paclitaxel (PTX) was purchased from Energy Chem. Co. Ltd. (Shanghai, China).
The DUP-1 peptide (CFRPNRAQDYNTN) was synthesised by standard solid-phase 
peptide synthesis method using Fmoc chemistry. The DUP1 peptide was purified by 
preperative high-pressure liquid chromatography on a Novasep LC50, C18-ODS-5 μm, 
250 × 50 mm column (Novasep, Pompey, France) using water, acetonitrile and metha-
nol as eluent solvent. All other solvents and reagents were of chemical grade and used 
without other purification. The ultrapure water was prepared from Milli-Q water system 
without specification.
PC-3 cell was purchased from the American Type Culture Collection (ATCC, Rock-
ville, MD, USA). PC-3 cells grew in Roswell Park Memorial Institute 1640 medium 
(RPMI 1640, Gibco, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum 
(FBS, Gibco, USA). All cells were maintained at 37 °C in humidified incubator contain-
ing 5 % CO2.
Synthesis of cholesterol–poly(ethylene glycol)–DUP1 peptides copolymers
The synthesis process of cholesterol–poly(ethylene glycol)–DUP1 copolymers (Chol–
PEG–DUP1) was followed our previous report; the synthetic route was showed in 
Scheme 1.
Fig. 1 Schematic representation of Chol–PEG–DUP1–M-PTX
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In general, the DMSO solution of Chol–PEG–Phe-NH2 (2.0 g, 0.76 mmol), and BMPS 
(0.24 g, 0.92 mmol) was stirred 24 h at room temperature to give a 3-maleimidopropionic 
acid modification on the PEG chain. Then the DUP-1 peptide (CFRPNRAQDYNTN, 
1.51 g, 0.92 mmol) was added and continuous stirred 12–24 h. After the reaction was 
completed, the solution was dialyzed to remove un-reacted peptides (membrane tubing, 
molecular weight cut off = 1.0 KD). The dialyzed product was lyophilized and the final 
products Chol–PEG–DUP1 (1.42 g, 47.1 %) was obtained.
Preparation and characterization of Chol–PEG–DUP1–M‑PTX
The paclitaxel loaded Chol–PEG–DUP1 micelles (M-PTX) were prepared as follow-
ing: PTX and copolymer (1:19, w/w) were dissolved in ethanol, and the solution was 
evaporated in rotary evaporator for 20 min to obtain the co-evaporation. Then, normal 
saline (NS) was added, and co-evaporation was dissolved to self-assemble into Chol–
PEG–DUP1–M-PTX. The obtained Chol–PEG–DUP1–M-PTX was first filtered using a 
0.22 μm Millex-LG filter (Millipore Co., Waltham, MA, USA), and then lyophilized into 
powder form before use.
The Malvern Nano-ZS 90 laser particle size analyzer (Malvern, Worcestershire, UK.) 
was utilized to the determination of particle size distribution and zeta potential of 
Scheme 1 Synthetic route of Chol–PEG–DUP1 copolymers
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Chol–PEG–DUP1–M-PTX. All the results were tested in three different samples, and 
data were expressed as the mean ±  standard deviation (SD). The morphological char-
acteristic of Chol–PEG–DUP1–M-PTX was further detected by transmission electron 
microscope (TEM, H-6009IV, Hitachi, Tokyo, Japan). The Chol–PEG–DUP1–M-PTX 
sample was negatively staining by phosphotungstic acid before TEM test.
The high performance liquid chromatography (HPLC, Waters Alliance 2695, Mil-
ford, MA, USA) instrument was used to determine the drug loading (DL) and encap-
sulation efficiency (EE) of Chol–PEG–DUP1–M-PTX with a ultra-violet (UV) detector, 
and chromatographic separations were performed on a reversed phase C18 column 
(4.6 × 150 mm, 5 μm, Inertsil/WondaSil, Japan). The DL and EE of Chol–PEG–DUP1–
M-PTX were calculated according to the following equations:
In vitro cytotoxicity
To investigate cytotoxicity of Chol–PEG–DUP1–M-PTX and free PTX, MTT assays 
were preformed on PC-3 cells. PC-3 cells cultured in 96-well plates were treated with a 
series of Chol–PEG–DUP1–M-PTX or free PTX for 48 h, respectively. The mean per-
centage of cell survival relative to that of control cells was determined from data of three 
individual experiments, and all the data were expressed as mean ± SD.
Apoptosis assay
Apoptosis induction assay of Chol–PEG–DUP1–M-PTX and free PTX were studied on 
PC-3 cells. PC-3 cells were plated in 6-well plates and grown for 24  h. The cells were 
exposed to media containing 20 ng/mL of Chol–PEG–DUP1–M-PTX and free PTX for 
48 h, respectively. Then, the cells were fixed with pre-chilled 70 % ethanol for 30 min and 
stained with 0.5 mL of PI (5 μg/mL in PBS) for 10 min. Apoptotic cells were observed 
under fluorescence microscopy (TE2000-U, Nikon, Tokyo, Japan), which demonstrated 
cytoplasmic and nuclear shrinkage and chromatin condensation.
Furthermore, flow cytometric (FCM) assay was used to confirm the apoptotic induc-
tion effect of Chol–PEG–DUP1–M-PTX. Apoptosis of PC-3 cells treated with PTX -M, 
free PTX, or blank micelles was determined using FITC-conjugated AnnexinV/PI (BD 
PharMingen, San Diego, CA, USA) staining by FCM (BD FACS Calibur, BD, San Jose, 
CA, USA). Both early apoptotic (Annexin V+/PI−) and late apoptotic (Annexin V+/PI+) 
cells were included in cell apoptosis determinations.
In vitro drug release
The release profiles of PTX from DUP1-modified micelles or free PTX were investigated 
by the dialysis method. Briefly, 1 mL of free PTX solution or drug loaded micelles were 
placed into dialysis bags (molecular weight cut off = 3500), then incubated at 37 °C with 
gentle shaking (100 rpm) in 50 mL of phosphate buffered solution (PBS) (PH 7.4 or PH 
5.5, 0.01 M) containing Tween80 (0.5 wt%). After given time intervals, dialysis medium 






(2)EE = Drug in micelles/drug in feed× 100%
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amount of released PTX were analyzed and quantified by HPLC. All the results were the 
mean value of three test runs and all data were shown as the mean ± SD.
Cellular uptake of micelles by flow cytometry analysis
In general, the PC-3 cells suspension (6 × 104 cells/well in 1.5 mL) were incubated at 
37  °C for 24  h in six-well plates (Corning, NY, USA). Then conventional micelles or 
DUP1-modified micelles loading the same amount of coumarine-6 (the final concentra-
tions were about 40 ng/mL) were added into each well, respectively. Then the six-well 
plates were further incubated at 37  °C for 1 h, the culture medium was discarded, the 
plates were digested with trypsin and the re-suspended cells were washed with cold PBS 
twice. Finally, each sample was examined by a flow cytometer (EPICS Elite ESP, Beck-
man Coulter, Brea, CA, USA). The fluoresces of intracellular coumarin-6 was excited at 
488 nm with an argon laser, and the emission fluorescence was detected at 525 nm. Files 
were collected of 10,000 gated events.
Immuno‑blotting analysis
The cellular total proteins were extracted using RIPA buffer (SolarBio, Beijing, China) 
containing 1 % (v/v) PMSF (SolarBio), 0.3 % (v/v) protease inhibitor (Sigma, St. Louis, 
MO, USA) and 0.1 % (v/v) phosphorylated proteinase inhibitor (Sigma). Celluar lysates 
were centrifuged at 13,000 rpm at 4 °C for 10 min, the supernatant was collected. The 
protein concentration was determined using BCA protein assay kit (Pierce, Waltham, 
MA, USA). The total protein was separated on SDS-PAGE gel and transferred onto a 
PVDF membrane. Non-specific interactions were blocked using skimmed milk for 2 h at 
room temperature. The PVDF membranes were incubated with the primary antibodies 
overnight at 4 °C. After washed several times, the PVDF membranes were incubated in 
HRP-conjugated goat anti-rabbit and anti-mouse IgG or HRP-conjugated mouse anti-
goat IgG (Abmart, Shanghai, China, all at a 1:5000 dilution) for 4–8 h at room tempera-
ture. The target proteins were visualized using enhanced chemiluminescence (Millipore, 
Billerica, MA, USA) according to the manufacturer’s recommendations.
Results and discussion
Synthesis and characterization of paclitaxel loaded micelles with or without DUP1 
modification
The synthesis of Chol–PEG–DUP1 was according to our previous reports with some 
modifications (He et al. 2012; Zeng et al. 2014). Figure 2 represents the 1H NMR spec-
trum of Chol–PEG–BMPS (PEG–cholesterol conjugate of (N-[β-maleimidopropyloxy] 
succinate) and Chol–PEG–DUP1, demonstrated the successful synthesis of Chol–PEG–
DUP1. As shown in Fig.  2, the multiplet peaks at δ 3.47–3.76 were attributed to the 
methylene group of repeating ethylene glycol units in PEG, and the six- and three posi-
tion protons in cholesterol were found as single peak at 5.36 and 4.59 ppm, respectively. 
The multiplet peaks around 4.24 ppm were assigned to the PEG methylene protons near 
the succinyl group, and the multiplet peaks at 2.70 were attributed to the methylene pro-
ton of succinyl group. All of the other multiple signals at 0.68–2.05 were the signals the 
protons in cholesterol. These results further showed that the conjugate had been suc-
cessfully prepared.
Page 7 of 14Chen et al. SpringerPlus  (2016) 5:362 
In our study, Chol–PEG–DUP1–M-PTX was prepared by a one-step solid dispersion 
method, the mean size of paclitaxel loaded micelles were fluctuated from 202 to 230 nm, 
with the different drug/polymer (w/w) ratio. The optimized polymer/drug ratio was 10:3, 
the optimized DL and EE were 24.9 ± 0.6 % and 96.40 ± 1.8 %, respectively. Further-
more, particle size, polydisperse index (PDI), and zeta potential of obtained PTX loaded 
Chol–PEG–DUP1 micelles were 202.5  ±  1.0  nm, 0.218  ±  0.032, and 12.6  ±  3.4  mV, 
respectively (Fig. 3a, b). Transmission electron microscopy (TEM) image of Chol–PEG–
DUP1–M-PTX was exhibited in Fig. 3c, and it indicated that the Chol–PEG–DUP1–M-
PTX was spherical in shape with a diameter of about 200 nm. The results of particle size 
analysis and microstructure of PTX observed by TEM suggested that a homogenous and 
stable solution of Chol–PEG–DUP1–M-PTX could be achieved by encapsulating PTX 
into polymeric micelles.
In vitro drug release profile
The in vitro release profile of paclitaxel from DUP1 peptide modified micelles (Chol–
PEG–DUP1–M-PTX) was studied at 37 °C and pH 7.4. Data suggest that paclitaxel can 
be well encapsulated in Chol–PEG–DUP1 micelles, and released in an extended period. 
As shown in Fig. 4, approximately 54 % of total drugs released after 24 h, followed by 
release of 78 % in 120 h. This cumulative drug release suggests potential applicability of 
these micelles as promising DDS that could result in a content pharmacokinetic profile 
in vivo and reduced exposure of healthy tissues.
Fig. 2 The 1H nuclear magnetic resonance spectrum (1H NMR) spectrum of Chol–PEG–BMPS and Chol–PEG–
DUP1 copolymers
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Cell uptake and binding study
To evaluate whether DUP1 peptide fragments could increase drug uptake by PSMA nega-
tive prostate tumor cells, PC-3 cells were treated with micelles encapsulated with couma-
rine-6. After incubation for a specific time, the cells were washed, then identified using 
fluorescence microscopy and collected for analysis of coumarine-derived fluorescence by 
flow cytometry. The flow cytometry data (Fig. 5a) shows the distribution of intensity in 
PC-3 cells treated with Chol–PEG–DUP1–M-Cou, Chol–mPEG–M-Cou, or empty Chol–
PEG2000–DUP1 micelles (Control). Mean fluorescence intensity of coumarine-6 uptake 
Fig. 3 Characterization of Chol–PEG–DUP1–M-PTX. a Particle size of Chol–PEG–DUP1–M-PTX; b zeta 
potential of Chol–PEG–DUP1–M-PTX; c TEM image of Chol–PEG–DUP1–M-PTX; d the effect of polymer/drug 
ratio on the encapsulation efficiency (EE), drug loading (DL) and size of Chol–PEG–DUP1–M-PTX [mean ± SD 
(standard derivations), n = 3]
Fig. 4 Time course of paclitaxel releasing from Chol–PEG–DUP1 micelle at 37 °C and pH 7.4. Released pacli-
taxel was separated by dialysis and quantified using high performance liquid chromatography (HPLC, error 
bars correspond to 95 % confidence intervals)
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by cells treated with Chol–PEG–DUP1–M-Cou was increased by 2.08-fold (mean fluores-
cence intensity = 54.7 vs. 113.8, p < 0.05) compared with that treated with Chol–mPEG–
M-Cou (Fig.  5). These results indicate that the DUP1 peptide fragments on the surface 
of micelles indeed enhanced the uptake of the drug (coumarine-6) in tumor cells. Which 
were further confirmed by fluorescence microscopy images (Fig. 6). Figure 6 is supported 
Chol–PEG–DUP1–M-Cou could effectively entry PC-3 prostate tumor cells, while less 
coumarine-6 was detected in cells that incubated with Chol–mPEG–M-Cou. When the 
PC-3 tumor cells were pre-incubated by free DUP1 peptides, the cellular uptake of Chol–
PEG–DUP1–M-Cou was obviously decreased, this further confirms the selectivity of 
Chol–PEG–DUP1 micelles to tumor cells were came from the DUP1 peptide fragments. 
In vitro cytotoxicity evaluation
In vitro cytotoxicity of Chol–PEG–DUP1–M-PTX and free PTX was determined by cell 
viability assay on PC-3 cells, and the results were shown in Fig. 7. With increase of PTX 
concentration, cell viabilities were decreased accordingly in all groups, but there was no sig-
nificant difference between Chol–mPEG–M-PTX and free PTX groups. After 48 h incuba-
tion with the free PTX, Chol–mPEG–M-PTX or Chol–PEG–DUP1–M-PTX, cytotoxicity 
was measured following the absorbance of the degraded MTT at 570  nm. As shown in 
Fig. 7, Chol–PEG–DUP1–M-PTX showed significantly higher cytotoxicity than free pacli-
taxel or Chol–mPEG–M-PTX. The mean concentrations of paclitaxel that caused 50 % cell 
inhibition (IC50) of Chol–PEG–DUP1–M-PTX was decreased to 15.83 μg/mL compared 
with 68.67 μg/mL of free paclitaxel and 65.76 μg/mL of Chol–mPEG–M-PTX, respectively.
In vitro apoptosis induction effect
In vitro apoptosis induction effect of Chol–PEG–DUP1–M-PTX was investigated 
using FCM assay of Annexin V/PI staining was employed to investigate the apoptosis 
induction effect of Chol–PEG–DUP1–M-PTX, and both early apoptosis (Annexin V+/
Fig. 5 Different cellular uptake of coumarine-6 loading micelles with or without DUP1 by PC-3 tumor cells. 
a Intracellular coumarine-6 fluorescence intensities in PC-3 cells after incubation with Chol–PEG–DUP1–M-
Cou (coumarine-6 loaded Chol–PEG–DUP1 micelles), Chol–mPEG–M-Cou (coumarine-6 loaded Chol–mPEG 
micelles), or empty Chol–PEG–DUP1 micelles (Control); b quantification of the mean fluorescence intensities 
of intracellular coumarine-6 from Chol–PEG–DUP1–M-Cou or Chol–mPEG–M-Cou, respectively
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PI−) and late apoptosis (Annexin V+/PI+) cells were included. According to Fig. 8, the 
percentage of apoptotic cells in Chol–PEG–DUP1–M-PTX group was 52.62 ± 7.12 %, 
which was significantly higher than that in free PTX (36.97 ± 5.75 %, p < 0.05), and NS 
(4.01 ±  0.74 %, p < 0.05) groups. There was no significant difference in late apoptosis 
between the Chol–PEG–DUP1–M-PTX (9.72 ± 2.15 %) and free PTX (9.87 ± 2.59 %, 
p  <  0.05) groups, but early apoptotic cells in the Chol–PEG–DUP1–M-PTX group 
(43.9 ± 5.09 %) were more than that in free PTX group (27.1 ± 3.64 %, p < 0.05). The 
Fig. 6 The fluorescence microscopy images (×40) of PC-3 tumor cells after incubation with different couma-
rine-6 loaded micelles: Control (a), the Chol–mPEG–M-Cou (b), free DUP1 + Chol–PEG–DUP1–M-Cou (c) and 
the Chol–PEG–DUP1–M-Cou (d)
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results of morphological observation and FCM assay suggested that, compared with free 
PTX, Chol–PEG–DUP1–M-PTX induced more apoptotic cells.
Immunoblotting analysis
To validate the expression of apoptosis related proteins in Chol–PEG–DUP1–M-PTX 
and free PTX treated PC-3 cells, immunoblotting assays were performed using examples 
of the death receptor pathway and mitochondrial pathway related to apoptotic proteins. 
Generally, apoptotic cell death is triggered by either the intrinsic pathway involving 
mitochondria or by the extrinsic pathway involving death receptors. The death receptor 
pathway can be initiated by stimulation of members of the death receptor family such 
as Fas, tumor necrosis factor related apoptosis-inducing ligand (TRAIL), and TNF-α. 
Initial mechanistic studies with Chol–PEG–DUP1–M-PTX and free PTX showed that 
the drug and drug loaded micelle only slightly increased levels of FasL, Fas-Associated 
protein with Death Domain (FADD), and cleaved caspase-8 in PC-3 cells (Fig. 9). This 
suggests that the apoptotic procedure barely involves the death receptor pathway. At the 
same time, Chol–PEG–DUP1–M-PTX and free PTX increased the amounts of Bax and 
cytosolic cytochrome c (Fig. 9), indicating that at least part of PTX and DUP1-M-PTX 
Fig. 7 The in vitro cytotoxicity of the free PTX, Chol–mPEG–M-PTX, and Chol–PEG–DUP1–M-PTX on PC-3 cell 
lines (48 h). The percentage of viable cells was quantified using the methylthiazoletetrazolium method. Mean 
values and 95 % confidence intervals derived from three independent experiments are shown, *p < 0.05
Fig. 8 Flow cytometric analysis of PC-3 cells stained with Annexin V-FITC/PI after treatment with control 
group (a), 10 μM of free PTX (b) or Chol–PEG–DUP1–M-PTX (c)
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induced apoptosis occurs via mitochondrial pathway. Since the release of cytochrome 
c from mitochondria can activate the proapoptotic caspase cascade, we investigated 
whether caspases 3 and 9 are involved. Treating PC-3 cells with PTX and drug loaded 
micelle increased levels of the cleaved forms of caspases 3 and 9 (Fig. 9). These results 
provided additional evidence that PTX induced apoptosis mainly occurred in the mito-
chondrial pathway, and the DUP1 modified micelle could enhance the apoptosis-induc-
ing capacity of PTX to PC-3 prostate cancer cells.
Conclusions
In conclusion, targeting peptide modified PEG–Chol polymeric micelles, the surfaces 
of which are conjugated with DUP1 peptide, have been prepared for PSMA negative 
PCa targeted drug delivery. The reported Chol–PEG–DUP1–M-PTX bearing both 
small particle size and high encapsulating efficiency. In vitro experiments suggested that 
Chol–PEG–DUP1–M-PTX had prior cytotoxicity than free drug in the cell prolifera-
tion MTT assays, and could inducing more apoptosis. Cellular flow cytometry results 
and fluorescence spectroscopy images suggest the surface DUP1 modification of the 
micelles promote the selective uptake by PSMA negative PC-3 cells. Although further 
in vivo antitumor investigation of Chol–PEG–DUP1–M-PTX is required, the results of 
our current study represent a meaningful explore in advancing the use of DUP1 pep-
tide modified micelles as a potent strategy to treat PSMA negative prostate cancer. Thus, 
Chol–PEG–DUP1–M-PTX may serve as a promising candidate for prostate cancer 
therapy.
Fig. 9 PTX and Chol–PEG–DUP1–M-PTX induces apoptosis via mitochondrial pathways in human prostate 
cancer PC-3 cells, as detected by Western blot analysis, glyceraldehyde phosphate dehydrogenase (GAPDH) 
served as a loading control
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